LIVIVO - Search results -

Search results

Result 1 - 10 of total 41

Search options

Article ; Online: Dalbavancin as chronic antibiotic suppression therapy for left ventricular assist device driveline infection due to methicillin-resistant

Pallotto, Carlo / Tordi, Sara / Pantanella, Romina / Rosignoli, Daniele / Francisci, Daniela

Journal of chemotherapy (Florence, Italy)

2022 Volume 35, Issue 5, Page(s) 465–469

Abstract: Left Ventricular Assist Devices (LVADs) represent an important therapeutic option in the management of advanced heart failure. We report a case of 74 years-old male with a Jarvik 2000® (Jarvik Heart, New York, USA) LVAD who presented with an infection of ...

Abstract	Left Ventricular Assist Devices (LVADs) represent an important therapeutic option in the management of advanced heart failure. We report a case of 74 years-old male with a Jarvik 2000® (Jarvik Heart, New York, USA) LVAD who presented with an infection of the LVAD driveline due to methicillin-resistant
MeSH term(s)	Humans ; Male ; Aged ; Methicillin-Resistant Staphylococcus aureus ; Heart-Assist Devices/adverse effects ; Quality of Life ; Anti-Bacterial Agents/therapeutic use ; Prosthesis-Related Infections/drug therapy
Chemical Substances	dalbavancin (808UI9MS5K) ; Anti-Bacterial Agents
Language	English
Publishing date	2022-10-25
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	1036294-0
ISSN	1973-9478 ; 1120-009X
ISSN (online)	1973-9478
ISSN	1120-009X
DOI	10.1080/1120009X.2022.2136426
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2701: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 387: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?

Gidari, Anna / Sabbatini, Samuele / Bastianelli, Sabrina / Pierucci, Sara / Busti, Chiara / Svizzeretto, Elisabetta / Tommasi, Andrea / Pallotto, Carlo / Schiaroli, Elisabetta / Francisci, Daniela

Viruses

2024 Volume 16, Issue 3

Abstract: Background: this study aims to evaluate the efficacy of tixagevimab/cilgavimab (Evusheld™) against various SARS-CoV-2 variants, including newer Omicron sublineages, in an immunocompromised cohort and in vitro.: Study design: Conducted in Italy, this ... ...

Abstract	Background: this study aims to evaluate the efficacy of tixagevimab/cilgavimab (Evusheld™) against various SARS-CoV-2 variants, including newer Omicron sublineages, in an immunocompromised cohort and in vitro. Study design: Conducted in Italy, this research involves immunocompromised patients who received Evusheld. It evaluates serum neutralization activity against different SARS-CoV-2 strains (20A.EU1, BA.5, BQ.1, XBB.1.5, XBB.1.16, and EG.5) before (T0), after 14 (T1), and after 30 (T2) days from the tixagevimab/cilgavimab injection. Furthermore, the in vitro activity of Evusheld against SARS-CoV-2 VOCs was evaluated. Results: The cohort was composed of 72 immunocompromised patients. The serum neutralizing activity of tixagevimab/cilgavimab-treated patients was notably lower against newer variants such as BQ.1, XBB.1.5, XBB.1.16, and EG.5. Then, the in vitro study detailed specific EC50 values to quantify the activity of tixagevimab/cilgavimab against various SARS-CoV-2 VOCs. Newer variants like BQ.1 and XBB.1.5 exhibited notably lower neutralization, underscoring the challenges in effectively countering the evolving virus. Interestingly, tixagevimab/cilgavimab maintained reduced but still valid activity against EG.5 with an EC50 of 189 ng/mL and Cmax/EC90 of 110.7. Conclusions: Tixagevimab/cilgavimab efficacy wanes against novel subvariants. This underscores the critical need for ongoing adaptation and vigilance in prophylactic strategies to effectively counter the dynamic and unpredictable nature of the COVID-19 pandemic.
MeSH term(s)	Humans ; COVID-19/prevention & control ; SARS-CoV-2/genetics ; Pandemics ; Antibodies, Monoclonal
Chemical Substances	tixagevimab ; cilgavimab (1KUR4BN70F) ; Antibodies, Monoclonal
Language	English
Publishing date	2024-02-25
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v16030354
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Chronic antibiotic suppressive therapy with dalbavancin: a case series.

Pallotto, Carlo / Tommasi, Andrea / Albagini, Margherita / Genga, Giovanni / Svizzeretto, Elisabetta / Gidari, Anna / Tordi, Sara / Francisci, Daniela

Journal of chemotherapy (Florence, Italy)

2024 , Page(s) 1–5

Abstract: Dalbavancin is a relatively new long-acting anti-Gram positive antimicrobial approved for the treatment of acute bacterial skin and skin structures infections. An increasing number of observational studies and case series were published on its off-label ... ...

Abstract	Dalbavancin is a relatively new long-acting anti-Gram positive antimicrobial approved for the treatment of acute bacterial skin and skin structures infections. An increasing number of observational studies and case series were published on its off-label uses. Great interest is emerging about complicated cases where antibiotic treatment cannot be discontinued, and a chronic suppressive therapy is needed. We described a case series of 6 patients treated or ongoing on treatment with dalbavancin as chronic suppressive therapy (CAST) administered with the following regimen: dalbavancin 1500 mg on day 1 and 8 and then every 4 weeks. CAST median duration was 27 weeks. Five out of 6 patients reached a good clinical control of the infection (one of them completely resolved) while in one case we observed a recurrence of the infection. No adverse events were detected. Larger studies are needed to better clarify dalbavancin off-label uses and the most appropriate dose regimen.
Language	English
Publishing date	2024-05-07
Publishing country	England
Document type	Journal Article
ZDB-ID	1036294-0
ISSN	1973-9478 ; 1120-009X
ISSN (online)	1973-9478
ISSN	1120-009X
DOI	10.1080/1120009X.2024.2349442
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2701: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 387: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Ceftobiprole Perspective: Current and Potential Future Indications.

Lupia, Tommaso / Pallotto, Carlo / Corcione, Silvia / Boglione, Lucio / De Rosa, Francesco Giuseppe

Antibiotics (Basel, Switzerland)

2021 Volume 10, Issue 2

Abstract: Ceftobiprole combines an excellent spectrum for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) pathogens, with a low/medium MDR risk, and the β-lactams' safety in frail patients admitted to the hospital in internal medicine ... ...

Abstract	Ceftobiprole combines an excellent spectrum for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) pathogens, with a low/medium MDR risk, and the β-lactams' safety in frail patients admitted to the hospital in internal medicine wards which may be at high risk of adverse events by anti-MRSA coverage as oxazolidinones or glycopeptides. We aimed to report the available evidence regarding ceftobiprole use in pneumonia and invasive bacterial infections, shedding light on ceftobiprole stewardship. The clinical application and real-life experiences of using ceftobiprole for bloodstream infections, including infective endocarditis, are limited but nevertheless promising. In addition, extended-spectrum ceftobiprole activity, including
Language	English
Publishing date	2021-02-08
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics10020170
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).

Pallotto, Carlo / Suardi, Lorenzo R / Gabbuti, Andrea / Esperti, Sara / Mecocci, Lorenzo / Blanc, Pierluigi

Journal of medical virology

2021 Volume 93, Issue 5, Page(s) 2631–2634

MeSH term(s)	Adenosine Monophosphate/administration & dosage ; Adenosine Monophosphate/adverse effects ; Adenosine Monophosphate/analogs & derivatives ; Aged ; Alanine/administration & dosage ; Alanine/adverse effects ; Alanine/analogs & derivatives ; Bradycardia/epidemiology ; Bradycardia/etiology ; COVID-19/drug therapy ; COVID-19/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors ; SARS-CoV-2 ; Treatment Outcome
Chemical Substances	remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
Language	English
Publishing date	2021-03-03
Publishing country	United States
Document type	Letter ; Observational Study
ZDB-ID	752392-0
ISSN	1096-9071 ; 0146-6615
ISSN (online)	1096-9071
ISSN	0146-6615
DOI	10.1002/jmv.26898
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1320: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Nelfinavir: An Old Ally in the COVID-19 Fight?

Gidari, Anna / Sabbatini, Samuele / Pallotto, Carlo / Bastianelli, Sabrina / Pierucci, Sara / Busti, Chiara / Schiaroli, Elisabetta / Francisci, Daniela

Microorganisms

2022 Volume 10, Issue 12

Abstract: After almost three years of the pandemic, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is still spreading around the world, causing notable sanitary and social issues. New antiviral therapies are constantly under investigation. However, ... ...

Abstract	After almost three years of the pandemic, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is still spreading around the world, causing notable sanitary and social issues. New antiviral therapies are constantly under investigation. However, few options have been approved for the treatment of COVID-19. Clinical trials are currently ongoing to evaluate the efficacy of nelfinavir on mild−moderate COVID-19. This study aims to investigate the activity of this compound on SARS-CoV-2 “Variants of Concern” (VOCs), comparing its effectiveness with the approved drugs remdesivir and molnupiravir. The experiments were conducted in a biosafety level 3 facility. In this study, we used a Vero-E6-cell-based infection assay to investigate the in vitro activity of nelfinavir, molnupiravir, and remdesivir. Four strains of SARS-CoV-2 were tested: 20A.EU1, B.1.1.7, P.1, and B.1.617.2. All compounds reached micromolar/submicromolar EC50, EC90, and EC99. Furthermore, the Cmax/EC50 and Cmax/EC90 ratios were >1 for all compounds and all variants tested. Our study demonstrated that nelfinavir, as molnupiravir, and remdesivir are effective in vitro on SARS-CoV-2 variants.
Language	English
Publishing date	2022-12-14
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2720891-6
ISSN	2076-2607
ISSN	2076-2607
DOI	10.3390/microorganisms10122471
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Acute gastroenteritis due to

Stolaj, Elisa / Belfiori, Barbara / Mercuri, Alessandra / Papili, Rita / Rosignoli, Daniele / Albagini, Margherita / Genga, Giovanni / Tommasi, Andrea / Veramonti, Dante / Pallotto, Carlo / Francisci, Daniela

IDCases

2023 Volume 33, Page(s) e01878

Abstract: ... Vibrio ... ...

Abstract	Vibrio cholerae
Language	English
Publishing date	2023-08-20
Publishing country	Netherlands
Document type	Case Reports
ZDB-ID	2745454-X
ISSN	2214-2509
ISSN	2214-2509
DOI	10.1016/j.idcr.2023.e01878
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry.

Esposito, Silvano / Pagliano, Pasquale / De Simone, Giuseppe / Guarino, Amedeo / Pan, Angelo / Brambilla, Paola / Mastroianni, Claudio / Lichtner, Miriam / Brugnaro, Pierluigi / Carretta, Anna / Santantonio, Teresa / Brindicci, Gaetano / Carrega, Giuliana / Montagnani, Francesca / Lapadula, Giuseppe / Spolti, Anna / Luzzati, Roberto / Schiaroli, Elisabetta / Scaglione, Vittoria /

Pallotto, Carlo / Tacconi, Danilo / Quintieri, Francesco / Trecarichi, Enrico

Infection

2024

Abstract: Purpose: Although dalbavancin is currently approved for the treatment of ABSSIs, several studies suggest its efficacy and tolerance as long-term therapy for other off-label indications requiring prolonged intravenous antibiotic administration.: ... ...

Abstract	Purpose: Although dalbavancin is currently approved for the treatment of ABSSIs, several studies suggest its efficacy and tolerance as long-term therapy for other off-label indications requiring prolonged intravenous antibiotic administration. Methods: We conducted a prospective nationwide study of dalbavancin use in real-life settings for both approved and off-label indications analysing for each case the clinical and microbiological characteristics of infection the efficacy and safety of treatments. Results: During the study period (from December 2018 to July 2021), the ID specialists from 14 different centres enrolled 223 patients treated with dalbavancin [141 males (63%) and 82 females (37%); male/female ratio 1.72; mean age 59 (SD 17.2) years, (range 15-96). Most patients in the study population (136/223; 61.0%) came from community rather than health care facilities and most of them were visited in Infectious Diseases wards (93/223; 41.7%) and clinics (55/223; 24.7%) even though some patients were cured in other settings, such as surgery wards (18/223; 8.1%), orthopaedic wards (11/223; 4.9%), Emergency Rooms (7/223; 3.1%) and non-surgical other than ID wards (6/223; 2.7%). The most common ID diagnoses were osteomyelitis (44 cases/223; 19.7%; of which 29 acute and 15 chronic osteomyelitis), cellulitis (28/223; 12.5%), cutaneous abscess (23/223; 10.3%), orthopaedic prosthesis-associated infection (22/223; 9.9%), surgical site infection (20/223; 9.0%) and septic arthritis (15/223; 6.7%). Conclusion: In conclusion, by virtue of its PK/PD properties, dalbavancin represents a valuable option to daily in-hospital intravenous or outpatient antimicrobial regimens also for off-label indications requiring a long-term treatment of Gram-positive infections.
Language	English
Publishing date	2024-02-07
Publishing country	Germany
Document type	Journal Article
ZDB-ID	185104-4
ISSN	1439-0973 ; 0300-8126 ; 0173-2129
ISSN (online)	1439-0973
ISSN	0300-8126 ; 0173-2129
DOI	10.1007/s15010-024-02176-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 881: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 528: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients.

Schiaroli, Elisabetta / Gidari, Anna / Brachelente, Giovanni / Bicchieraro, Giulia / Spaccapelo, Roberta / Bastianelli, Sabrina / Pierucci, Sara / Busti, Chiara / Pallotto, Carlo / Malincarne, Lisa / Camilloni, Barbara / Falcinelli, Flavio / De Socio, Giuseppe Vittorio / Villa, Alfredo / Mencacci, Antonella / Francisci, Daniela

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

2023 Volume 168, Page(s) 105584

Abstract: Background: Tixagevimab-cilgavimab has been approved as primary pre-exposure prophylaxis in immunocompromised patients as support or replacement for vaccination, even though the Omicron variant of concern (VOC) was spreading at the time.: Objectives: ...

Abstract	Background: Tixagevimab-cilgavimab has been approved as primary pre-exposure prophylaxis in immunocompromised patients as support or replacement for vaccination, even though the Omicron variant of concern (VOC) was spreading at the time. Objectives: The aim of our study was to evaluate the post-injection neutralising activity (NT Study design: NT Results: At baseline, 35.2%, 37.02%, and 32.5% of booster vaccinated patients exhibited undetectable levels of anti-S and anti-RBD IgG antibodies such as NT Conclusions: To date, tixagevimab-cilgavimab cannot be considered a substitute for vaccination but may be a useful supporting therapy if the recommended dose for pre-exposure prophylaxis is doubled.
MeSH term(s)	Humans ; Antibodies, Neutralizing ; Pre-Exposure Prophylaxis ; Immunocompromised Host ; SARS-CoV-2 ; Immunoglobulin G ; Antibodies, Viral
Chemical Substances	tixagevimab ; cilgavimab (1KUR4BN70F) ; Antibodies, Neutralizing ; Immunoglobulin G ; Antibodies, Viral
Language	English
Publishing date	2023-09-17
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1446080-4
ISSN	1873-5967 ; 1386-6532
ISSN (online)	1873-5967
ISSN	1386-6532
DOI	10.1016/j.jcv.2023.105584
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3790: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Adherence to 2015 ESC Guidelines for the Treatment of Infective Endocarditis: A Retrospective Multicentre Study (LEIOT Study).

Pallotto, Carlo / Bolla, Cesare / Penpa, Serena / Genga, Giovanni / Sarda, Cristina / Svizzeretto, Elisabetta / Tommasi, Andrea / Stolaj, Elisa / Salvaderi, Andrea / Piceni, Giorgia / Maconi, Antonio / Chichino, Guido / Francisci, Daniela / On Behalf Of The Leiot Study Group

Antibiotics (Basel, Switzerland)

2023 Volume 12, Issue 4

Abstract: Background: Infective endocarditis (IE) is still a severe disease with elevated morbidity and mortality. Nevertheless, the last European guidelines (GL) date back to 2015, and a recent survey described a diffuse suboptimal adherence to their ... ...

Abstract	Background: Infective endocarditis (IE) is still a severe disease with elevated morbidity and mortality. Nevertheless, the last European guidelines (GL) date back to 2015, and a recent survey described a diffuse suboptimal adherence to their recommendations. Here, we described a real-life scenario about adherence to IE treatment GL. Methods: This was a retrospective, multicentric, case-control study. All the cases of IE admitted to our wards from 2016 to 2020 were enrolled. Patients were divided into two groups, according to the non-adherence (group A, cases) or adherence (group B, controls) to 2015 ESC guidelines. Only targeted treatments were considered. Groups were compared for demographic, clinical, microbiological, and laboratory data and outcome. As a post hoc analysis, we analysed the characteristics of deviations from the guidelines and how these deviations affected mortality. Results: A total of 246 patients were enrolled, with 128 (52%) in group A and 118 (48%) in group B. Groups were homogeneous except for aetiologies: staphylococcal and blood-culture-negative IE were more frequent in group A, while streptococcal and enterococcal IE were more frequent in group B ( Conclusions: Adherence to 2015 ESC guidelines was limited but it did not affect mortality.
Language	English
Publishing date	2023-04-04
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2681345-2
ISSN	2079-6382
ISSN	2079-6382
DOI	10.3390/antibiotics12040705
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito